Drug Overview

Synthetic hTERT DNA vaccine INO 1400 is a sophisticated cancer treatment designed to train the body’s immune system to recognize and kill tumor cells. It is widely considered a “Smart Drug” because it falls under the categories of both Immunotherapy and Targeted Therapy. Unlike traditional vaccines that protect against viruses, this DNA vaccine is engineered to target a specific protein called telomerase reverse transcriptase (hTERT).

For patients and healthcare providers, INO 1400 represents a high-tech approach to oncology. It uses the body’s own genetic instructions to create a defense against cancer. By targeting a protein that is found in nearly all types of cancer but is mostly absent in healthy cells, it aims to provide a precise strike against the disease while sparing normal tissues.

• Generic name: Synthetic hTERT DNA vaccine INO 1400
• US Brand names: None (Currently an investigational drug)
• Drug Class: DNA Vaccine; Immunotherapy; Cancer Vaccine
• Route of Administration: Intramuscular (IM) injection followed by electroporation
• FDA Approval Status: Investigational (Currently in Phase 1 and Phase 2 clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

Synthetic hTERT DNA vaccine INO 1400 works by delivering genetic “blueprints” directly into your cells. To understand how it works at the molecular level, we look at the interaction between DNA technology and the human immune system.

The vaccine targets hTERT, an enzyme that cancer cells use to stay “immortal.” Normal cells eventually stop dividing and die, but cancer cells use hTERT to repair the ends of their chromosomes, allowing them to multiply forever.

The mechanism involves several key steps:

1. Delivery via Electroporation: The DNA vaccine is injected into a muscle. Immediately after, a specialized device sends a brief, controlled pulse of electricity to the area. This process, called electroporation, creates tiny, temporary pores in the cell membranes, allowing the DNA instructions to enter the cells.
2. Protein Production: Once inside the cell, the DNA travels to the nucleus. The cell’s own machinery reads the DNA and produces a synthetic version of the hTERT protein. This protein is harmless on its own but acts as a “wanted poster” for the immune system.
3. Antigen Presentation: The cell breaks down the synthetic hTERT and displays small pieces of it on its surface using Major Histocompatibility Complex (MHC) molecules.
4. T-Cell Activation: Specialized immune cells called T-cells find these hTERT pieces. The vaccine is designed to specifically activate “Killer T-cells” (CD8 positive) and “Helper T-cells” (CD4 positive).
5. Systematic Surveillance: These trained T-cells then travel through the bloodstream. When they encounter a cancer cell displaying hTERT, they recognize it as an enemy and release chemicals to destroy it. This creates a long-lasting “immune memory” to help the body fight the cancer if it tries to return.

FDA-Approved Clinical Indications

As an investigational drug, INO 1400 does not yet have official FDA approval for general medical use. It is currently being studied in international clinical trials for the following:

Oncological uses

• Investigational treatment for advanced solid tumors (including lung, head and neck, and esophageal cancers).
• Investigational research for Glioblastoma (aggressive brain cancer).
• Investigational treatment for high-risk Breast Cancer and Ovarian Cancer.
• Research into combination therapies with other Immunotherapies (like PD-1 inhibitors).

Non-oncological uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

In clinical research settings, INO 1400 is administered using the Cellectra device for electroporation. The dose is designed to be given in a series to build and maintain the immune response.

Dose Adjustments

Because this is a DNA vaccine that stays mostly in the muscle and local lymph nodes, traditional dose adjustments for renal (kidney) or hepatic (liver) insufficiency are not typically required. However, the skin and muscle at the injection site must be healthy enough to undergo the electroporation process.

Clinical Efficacy and Research Results

Clinical research data from 2020 to 2025 has focused on how well the vaccine generates an immune response (immunogenicity) and its effect on survival.

Numerical data from early Phase 1 trials showed that INO 1400 was safe and well-tolerated in nearly 100 percent of participants. In studies involving patients with various solid tumors, research results indicated that over 90 percent of patients developed a measurable T-cell response against hTERT after the third dose. Current 2024 and 2025 data from Phase 2 trials are exploring survival rates. Preliminary results suggest that when INO 1400 is combined with other “Smart Drugs,” it may help stabilize the disease for several months longer than standard treatments alone. While survival numbers are still being finalized, the evidence shows that the vaccine successfully “teaches” the immune system to recognize the tumor.

Safety Profile and Side Effects

The safety profile of INO 1400 is unique because it combines a vaccine with a medical device.

Black Box Warning

There is no official Black Box Warning for INO 1400.

Common side effects

These occur in more than 10 percent of patients and are mostly related to the injection site:

• Pain or discomfort at the injection site (related to electroporation).
• Redness, swelling, or bruising where the vaccine was given.
• Feeling very tired (fatigue).
• Low-grade fever or chills shortly after the injection.
• Muscle aches.

Serious adverse events

• Severe skin or muscle irritation at the injection site.
• Rare systemic allergic reactions (anaphylaxis).
• Immune-mediated inflammation of healthy organs (monitored by blood work).

Management strategies

Injection site pain is usually temporary and resolves within a few minutes to hours. Over-the-counter pain relievers like acetaminophen can manage fever and muscle aches. If a patient develops a severe rash or trouble breathing, they are treated with standard allergy medications.

Research Areas

INO 1400 is a major focus in Research Areas involving “Universal Cancer Vaccines.” Because hTERT is found in over 85 percent of all human cancers, scientists are studying if this drug can be used as a “one-size-fits-all” immunotherapy. There is also active research in the field of regenerative medicine and stem cell therapies to see if hTERT-targeted vaccines can be used to eliminate “Cancer Stem Cells,” which are often resistant to chemotherapy. Currently, the most active 2025 research is looking at using INO 1400 alongside “Checkpoint Inhibitors” to remove the “brakes” on the immune system while the vaccine provides the “gas.”

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Blood tests to check the baseline immune system.
• Imaging (CT or MRI) to measure the baseline tumor size.
• Skin assessment at the injection site (usually the deltoid or thigh).

Precautions during treatment

Patients should be aware that the electroporation process feels like a strong, brief muscle twitch or a “snap.” It is important to stay still during the procedure to ensure the DNA enters the cells correctly.

Do’s and Don’ts list

• Do tell your doctor if you have an implanted electronic device (like a pacemaker), as the electroporation device may interfere with it.
• Do keep the injection site clean and dry for 24 hours.
• Do report any persistent fever or unusual fatigue.
• Don’t apply heat or ice to the injection site unless your research team says it is okay.
• Don’t skip your scheduled doses, as the “booster” shots are necessary for long-term protection.
• Don’t take high doses of steroids unless medically necessary, as they can weaken the vaccine’s effect.

Legal Disclaimer

The information in this guide is for educational and informational purposes only and does not constitute medical advice. Synthetic hTERT DNA vaccine INO 1400 is an investigational drug and is not approved by the Food and Drug Administration (FDA) for general use outside of clinical trials. Always consult with a qualified healthcare professional or your oncologist before making any decisions regarding your medical treatment.